articl
review
pulmonari
rout
administr
aerosol
deliveri
devic
character
pulmonari
drug
deliveri
system
discuss
rational
inhal
deliveri
sirna
diseas
known
protein
malfunct
may
mitig
use
sirna
therapeut
inhal
rout
administr
provid
local
deliveri
sirna
therapeut
treatment
variou
pulmonari
diseas
howev
barrier
pulmonari
deliveri
intracellular
deliveri
sirna
exist
sirna
load
nanocarri
use
overcom
barrier
associ
pulmonari
rout
anatom
barrier
mucociliari
clearanc
alveolar
macrophag
clearanc
apart
nake
sirna
aerosol
deliveri
previous
studi
sirna
carrier
system
compris
lipid
polymer
peptid
inorgan
origin
sirna
deliveri
system
formul
aerosol
success
deliv
via
inhal
nebul
pulmonari
region
preclin
anim
investig
inhal
sirna
therapeut
reli
intratrach
intranas
sirna
sirna
nanocarri
deliveri
aerosol
sirna
deliveri
system
may
character
use
vitro
techniqu
dissolut
test
inerti
cascad
impact
deliv
dose
uniform
assay
laser
diffract
laser
doppler
velocimetri
ex
vivo
techniqu
use
character
pulmonari
administ
formul
includ
isol
perfus
lung
model
vivo
techniqu
like
gamma
scintigraphi
spect
pet
mri
fluoresc
imag
pharmacokineticpharmacodynam
analysi
may
use
evalu
aerosol
sirna
deliveri
system
use
inhal
sirna
deliveri
system
encount
barrier
deliveri
howev
overcom
barrier
formul
safe
effect
deliveri
system
offer
uniqu
advanc
field
inhal
medicin
rna
interfer
rnai
process
rna
molecul
inhibit
gene
express
caus
destruct
specif
messeng
rna
mrna
small
interf
rna
sirna
doubl
strand
rna
molecul
contain
nucleotid
involv
rnai
pathway
interfer
express
specif
gene
complementari
nucleotid
sequenc
agraw
n
et
al
shown
fig
sirna
degrad
mrna
transcript
therebi
prevent
translat
play
role
rnairel
pathway
agraw
n
et
al
sirna
potenti
therapeut
applic
treat
undrugg
diseas
downregul
express
target
gene
posttranscript
manner
sinc
discoveri
sirna
fire
mello
et
al
mechan
rnai
extens
review
fellmann
c
low
sw
fire
et
al
hannon
gj
kim
dh
rossi
jj
sirna
possess
specif
sequenc
complementari
target
mrna
induc
sitespecif
cleavag
subsequ
inhibit
intracellular
protein
synthesi
sirna
cytoplasm
cell
incorpor
within
rnainduc
silenc
complex
risc
activ
complex
sens
strand
remov
duplex
degrad
nucleas
activ
risc
complex
time
antisens
strand
direct
risc
basecomplementari
sequenc
target
mrna
locat
within
cell
cytoplasm
bind
mrna
antisens
strand
activ
risc
eventu
induc
cleavag
endonucleas
argonaut
posttranscript
silenc
target
gene
express
major
advantag
sirna
small
molecul
drug
protein
therapeut
sequenc
rapidli
design
highli
specif
inhibit
target
interest
synthesi
sirna
rel
simpl
requir
cellular
express
system
complex
protein
purif
refold
scheme
amarzguioui
et
al
pulmonari
diseas
lung
cancer
cystic
fibrosi
pulmonari
hypertens
asthma
chronic
obstruct
pulmonari
disord
copd
potenti
sirna
therapeut
target
amarzguioui
et
al
burnett
jc
rossi
jj
kanasti
r
et
al
nevertheless
sirna
deliveri
system
like
instabl
issu
caus
prematur
releas
nucleic
acid
especi
system
incorpor
cargo
electrostat
interact
due
high
neg
charg
densiti
rel
larg
size
sirna
molecul
nake
sirna
molecul
abl
enter
cell
effici
reischl
zimmer
pulmonari
deliveri
sirna
face
major
challeng
involv
lack
correl
vitro
vivo
experi
difficulti
translat
anim
model
human
nonapplic
administr
rout
use
anim
studi
human
use
lam
jkw
et
al
part
review
mode
pulmonari
deliveri
sirna
evalu
aerosol
drug
deliveri
system
rational
use
nanocarri
overcom
barrier
pulmonari
deliveri
cellular
uptak
sirna
part
ii
focus
sirna
load
nonvir
particul
aerosol
deliveri
system
prepar
character
techniqu
sirna
load
nanoparticl
achiev
pulmonari
deliveri
inhal
aerosol
gener
inhal
nebul
prefer
option
enter
clinic
trial
new
therapeut
agent
must
demonstr
preclin
efficaci
appropri
anim
model
translat
human
laub
bl
pulmonari
aerosol
usual
administ
via
inhal
intratrach
intranas
rout
intratrach
intranas
rout
administr
commonli
use
deliv
therapeut
sirna
therapeut
agent
lung
anim
due
eas
experiment
setup
control
driscol
ke
et
al
preclin
studi
differ
lung
anatomi
mice
human
need
consid
select
rout
administr
assess
deliveri
efficaci
formul
administ
via
pulmonari
rout
administr
requir
nonirrit
reduc
risk
pharyng
edema
bronchial
spasm
anaphylaxi
peracut
death
chronic
pulmonari
fibrosi
turner
pv
et
al
factor
vital
success
develop
oral
intranas
inhal
sirna
deliveri
system
noninvas
way
local
deliv
therapeut
lung
inhal
four
type
inhal
devic
current
avail
includ
pressur
meter
dose
inhal
pmdi
dri
powder
inhal
dpi
nebul
soft
mist
inhal
smi
appropri
development
optim
devic
may
deliv
sirna
lung
develop
key
paramet
consid
optimum
inhal
system
shown
tabl
inhal
aerosol
deliveri
devic
pmdi
current
commonli
use
inhal
therapeut
agent
within
pmdi
either
suspend
particul
state
dissolv
within
propel
chlorofluorocarbon
cfc
hydrofluoroalkan
hfa
lam
jkw
et
al
propel
indispens
part
pmdi
suppli
energi
requir
aerosol
drug
inhal
sirna
sirna
load
nanocarri
may
compat
propel
vehicl
limit
formul
sirna
pmdi
lam
jkw
et
al
howev
crosslink
base
nanocarri
particl
size
less
nm
found
physic
stabl
within
highli
dispers
fougerol
novobrantseva
de
fougerol
et
al
copyright
success
deliv
deep
lung
airway
use
pmdi
sharma
k
et
al
select
stabl
appropri
formul
use
pmdi
devic
allow
develop
sirna
contain
pmdi
dpi
formul
allow
inhal
aerosol
cloud
dri
particl
dpi
devic
design
major
impact
perform
advantag
dpi
improv
steril
chemic
stabil
biomolecul
compar
liquid
aerosol
lam
j
kw
et
al
drug
deposit
inhal
dpi
depend
inspir
flow
rate
patient
often
time
ill
warrant
use
inhal
therapi
caus
inspir
flow
rate
abnorm
low
feddah
mr
et
al
ross
dl
schultz
rk
devic
must
design
minim
variat
respect
patient
diseas
state
shoyel
sa
slowey
spray
dri
techniqu
often
use
prepar
protein
peptid
inhal
dpi
formul
demonstr
success
vivo
deliveri
therapeut
macromolecul
bai
et
al
codron
v
et
al
mastrandrea
ld
quattrin
rawat
et
al
dpi
formul
use
pulmonari
deliveri
sirna
issu
challeng
risen
formul
biolog
macromolecul
flowabl
dispers
biochem
stabil
need
also
consid
develop
sirna
base
dpi
chan
hk
consider
formul
protein
powder
aerosol
review
previous
chan
hk
maintain
biochem
stabil
sirna
formul
limit
process
may
use
prepar
sirna
base
dri
powder
formul
nebul
gener
liquid
aerosol
deliv
salinebas
solut
suspens
drug
product
larg
volum
via
inhal
sharma
k
et
al
nebul
treatment
usual
last
sever
minut
rather
singl
inhal
gener
droplet
aerodynam
diamet
depend
formul
type
nebul
devic
four
major
categori
nebul
jet
pneumat
vibrat
meshmembran
smart
ultrason
nebul
ari
dailey
la
et
al
jet
pneumat
nebul
use
deliv
suspens
formul
deliveri
suspens
formul
make
suitabl
deliv
sirna
sirna
carrier
deliveri
system
breathenhanc
jet
nebul
releas
aerosol
inhal
wherea
breathactu
jet
nebul
sens
patient
inspiratori
flow
deliv
aerosol
inhal
arunthari
v
et
al
hayn
jm
ho
sl
et
al
air
jet
nebul
compress
ga
draw
bulk
liquid
jet
bernoulli
effect
atom
take
place
liquid
emerg
jet
interact
shear
forc
set
ga
flow
rayleigh
dispers
bulk
liquid
droplet
occur
baffl
remov
coars
droplet
fall
back
reservoir
wherea
droplet
aerodynam
diamet
avail
inhal
estim
gener
aerosol
recycl
back
reservoir
thu
shear
stress
exert
multipl
time
formul
henc
possibl
degrad
nake
sirna
process
need
evalu
agu
ru
et
al
vibrat
mesh
nebul
use
micropump
forc
liquid
mesh
apertur
plate
aerosol
gener
suspens
nanocarri
nucleic
acid
success
deliv
via
mesh
nebul
elhissi
et
al
elhissi
taylor
k
hibbitt
et
al
lentz
yk
et
al
luo
et
al
wagner
et
al
yoshiyama
et
al
mesh
nebul
consist
improv
aerosol
gener
effici
larg
fineparticl
fraction
low
residu
volum
abil
nebul
low
volum
ari
dhand
r
dolovich
mb
dhand
r
waldrep
j
dhand
r
vibrat
mesh
membran
nebul
expens
jet
nebul
electron
involv
control
vibrat
process
addit
mesh
nebul
airway
structur
diamet
difficult
clean
howev
mesh
nebul
effici
jet
nebul
provid
higher
drug
dose
patient
ari
limit
mesh
nebul
includ
block
mesh
apertur
nebul
viscou
suspens
precipit
crystal
drug
excipi
ari
najlah
et
al
consider
formul
sirna
nanocarri
suspens
nebul
two
type
vibrat
mesh
nebul
term
activ
passiv
activ
mesh
nebul
util
piezoelectr
element
expand
contract
upon
applic
electr
current
vibrat
mesh
contact
medic
gener
aerosol
passiv
mesh
nebul
use
transduc
horn
induc
passiv
vibrat
mesh
plate
aerosol
gener
ari
smart
nebul
incorpor
adapt
aerosol
deliveri
aad
technolog
analyz
patient
breath
pattern
order
determin
time
aerosol
drug
deliveri
inhal
denyer
j
dych
devic
abl
adapt
patient
breath
pattern
therefor
abl
reduc
aerosol
loss
variat
drug
deliveri
smart
nebul
provid
effect
end
dose
feedback
patient
therapi
increas
patient
complianc
denyer
j
dych
denyer
j
et
al
ultrason
nebul
util
piezoelectr
crystal
vibrat
high
frequenc
mhz
produc
aerosol
type
nebul
limit
larg
residu
volum
inabl
aerosol
viscou
solut
degrad
heat
sensit
materi
ari
ari
et
al
ari
restrepo
rd
therefor
ultrason
nebul
may
use
suspens
nake
sirna
sirna
nanocarri
taylor
km
mccallion
watt
ab
et
al
chemic
physic
stabil
nake
sirna
nebul
process
high
concern
therefor
deliveri
sirna
use
nebul
involv
develop
formul
protect
sirna
physic
degrad
shear
stress
chemic
degrad
mediat
via
hydrolysi
endogen
enzym
lam
jkw
et
al
smi
recent
introduc
categori
inhal
deliveri
system
market
respimat
produc
boehringeringelhem
dalbi
r
et
al
technolog
provid
meter
dose
user
activ
inhal
energi
spring
impos
pressur
liquid
contain
smi
gener
aerosol
imping
oppos
droplet
stream
emerg
uniblock
nozzl
creat
use
silicon
wafer
technolog
dalbi
r
et
al
advantag
smi
high
lung
deposit
due
low
veloc
aerosol
cloud
thu
minim
deposit
mouth
throat
dalbi
r
et
al
hochrain
et
al
addit
patient
requir
exert
excess
inspiratori
forc
gener
aerosol
cloud
associ
dpi
effect
physic
chemic
stabil
sirna
must
consid
deliv
formul
via
smi
merkel
om
et
al
sharma
k
et
al
feasibl
smi
deliveri
devic
nonvir
sirna
deliveri
explor
may
viabl
option
intratrach
rout
administr
use
often
anim
studi
assess
inhal
deliveri
variou
drug
howev
clinic
applic
rout
limit
due
invas
setup
uncomfort
deliveri
techniqu
driscol
ke
et
al
sakagami
intratrach
rout
feasibl
human
clinic
studi
due
method
invas
involv
insert
tube
dispens
formul
within
surgic
incis
made
within
tracheal
ring
lam
jkw
et
al
tradit
method
involv
anim
anesthet
undergo
surgic
tracheotomi
trachea
expos
endotrach
tube
needl
insert
incis
tracheal
cartilagin
ring
tip
project
defin
posit
tracheal
bifurc
shown
fig
drug
solut
suspens
formul
administ
tube
use
microsyring
instil
airway
bivasbenita
et
al
describ
noninvas
intratrach
instil
involv
surgic
resect
trachea
also
known
orotrach
rout
bivasbenita
et
al
aerosol
deliv
lung
place
microspray
anesthet
anim
tongu
trachea
anim
intub
drug
instil
solut
suspens
form
method
drawback
diffi
culti
accur
placement
microspray
cathet
reduc
mucociliari
clearanc
due
anesthesia
number
studi
util
intratrach
rout
sirna
deliveri
lung
cond
j
et
al
garbuzenko
ob
et
al
merkel
om
et
al
moscho
sa
et
al
perl
et
al
rosastaraco
ag
et
al
wang
jc
et
al
drug
deposit
rout
less
uniform
inhal
rout
administr
sakagami
sinc
rout
avoid
oropharynx
deposit
amount
drug
loss
lower
compar
inhal
rout
howev
rout
deliveri
allow
determin
effect
aerodynam
particl
size
lung
deposit
therefor
vivo
intratrach
instil
studi
anim
reflect
intricaci
lung
deposit
intratrach
instil
rout
deliveri
suitabl
provid
proofofconcept
local
lung
deliveri
studi
anim
model
intratrach
aerosol
devic
consist
atom
locat
distal
tip
long
narrow
stainless
steel
plastic
tube
use
deliv
aerosol
directli
lung
insert
trachea
carina
anesthet
anim
devic
preclin
studi
includ
commerci
avail
technolog
administr
solut
dri
powder
aerosol
formul
intratrach
deliveri
achiev
devic
penncenturi
microspray
gutbier
b
et
al
rosastaraco
ag
et
al
micromist
nebul
zamoraavila
et
al
aeroprob
nebul
cathet
nielsen
ej
et
al
penncenturi
inc
wyndmoor
pa
usa
offer
airfre
liquid
devic
airdriven
dri
powder
devic
preclin
use
bivasbenita
et
al
morello
et
al
miniatur
nebul
cathet
system
shown
success
target
gene
deliveri
lung
kopinghoggard
et
al
trond
et
al
nebul
cathet
devic
ncd
first
adapt
deliveri
peptid
therapeut
rat
lung
aeroprob
tm
trudel
medic
intern
london
ontario
canada
trond
et
al
ncd
deliv
liquid
transport
tube
central
lumen
pressur
ga
push
peripher
lumen
compress
airway
sourc
psi
close
proxim
liquid
ga
lumen
distal
tip
produc
aerosol
particl
size
rang
trond
et
al
intranas
rout
provid
straight
forward
anim
model
experiment
setup
deliveri
sirna
lung
therefor
anoth
common
sirna
deliveri
rout
bitko
v
et
al
fulton
et
al
ghosn
b
et
al
gutbier
b
et
al
hosoya
k
et
al
howard
ka
et
al
li
bj
et
al
massaro
et
al
senoo
et
al
tompkin
sm
et
al
zhang
x
et
al
anim
must
anesthet
sirna
formul
instil
nasal
caviti
breath
although
rout
shown
success
sirna
deliveri
lung
mous
anim
model
translat
studi
human
limit
human
oblig
nose
breather
nasal
caviti
filter
major
particul
therefor
human
intranas
studi
see
high
lung
deposit
hickey
aj
garciacontrera
l
addit
anesthet
caus
anim
reduc
mucociliari
action
therefor
reduc
mucociliari
clearanc
overestim
transfect
effici
formul
hinchcliff
illum
l
studi
heyder
et
al
found
monodispers
powder
particl
aerodynam
diamet
deposit
within
human
bronchial
airway
intranas
administr
heyder
j
et
al
sinc
approxim
monodispers
particl
deposit
within
nasopharynx
area
intranas
rout
deliveri
ideal
target
site
human
sirna
target
mrna
encod
nprotein
respiratori
syncyti
viru
rsv
develop
alnylam
pharmaceut
cambridg
usa
complet
phase
ii
clinic
trial
treatment
human
rsb
infect
use
intranas
rout
administr
devincenzo
j
et
al
devincenzo
j
et
al
zamora
mr
et
al
nake
sirna
deliv
via
nasal
spray
upper
respiratori
tract
intranas
rout
may
also
use
allow
system
central
nervou
system
cn
deliveri
sirna
protein
peptid
biolog
macromolecul
previous
administ
via
intranas
rout
access
system
circul
hinchcliff
illum
l
nasal
caviti
rel
larg
surfac
area
vascular
facilit
rapid
absorpt
intranas
rout
access
cn
bypass
bloodbrain
barrier
hanson
lr
frey
wh
kamei
n
takedamorishita
intranas
deliveri
devic
liquid
solut
suspens
includ
rhinyl
cathet
instil
tube
simpl
method
often
use
anesthet
sedat
anim
involv
intranas
insert
fine
cathet
micropipett
follow
instil
liquid
desir
area
aspir
airway
breath
fernand
ca
vanbev
r
use
small
volum
per
nostril
total
limit
drug
deposit
nasal
caviti
wherea
larger
volum
per
nostril
total
allow
deposit
lung
upper
airway
minn
et
al
intranas
instil
limit
due
hinder
abil
reach
deep
lung
intranas
deliveri
dri
powder
pulmonari
rout
administr
dri
powder
insuffl
tm
mice
use
aerosol
powder
dose
sinsuebpol
c
et
al
devic
actuat
use
either
air
syring
penncenturi
air
pump
gener
puff
air
gener
powder
dose
carri
deep
lung
aerosol
exposur
chamber
may
classifi
noseonli
headonli
wholebodi
exposur
chamber
system
commonli
use
deliv
nebul
formul
cryan
sa
et
al
exampl
noseonli
exposur
chamber
inexpos
tm
scireq
model
shown
fig
devic
evalu
use
inhal
drug
carrier
system
contain
antisens
oligonucleotid
sirna
treatment
lung
cancer
main
g
et
al
liposom
particl
size
mass
median
diamet
nm
nm
respect
aerosol
jet
collison
nebul
found
stabl
continu
aerosol
higher
lung
dose
retent
time
compar
intraven
rout
observ
main
g
et
al
exampl
noseonli
exposur
chamber
includ
oronas
respiratori
exposur
system
ch
technolog
westwood
nj
intox
product
small
anim
exposur
system
intox
product
edgewood
nm
noseonli
headonli
exposur
chamber
avoid
exposur
aerosol
part
bodi
setup
stress
anim
due
restraint
exposur
facemask
place
anim
face
neck
cryan
sa
et
al
wholebodi
exposur
setup
repres
less
invas
exposur
chamber
rodent
free
move
passiv
aerosol
deliveri
cryan
sa
et
al
wholebodi
exposur
also
simul
environment
exposur
aerosol
c
et
al
exposur
chamber
usual
compos
chamber
anim
resid
aerosol
therapi
port
aerosol
deliv
insid
chamber
adamcakova
dodd
et
al
oshaughnessi
pt
et
al
petti
rj
et
al
deliv
therapeut
aerosol
via
wholebodi
exposur
chamber
possibl
administr
signific
amount
formul
rout
oral
rout
cryan
sa
et
al
paramet
impact
variat
studi
may
includ
size
chamber
anim
size
lung
capac
inspiratori
flow
rate
formul
characterist
cryan
sa
et
al
aerosol
sirna
formul
character
use
variou
vitro
ex
vivo
vivo
techniqu
mansour
hm
et
al
newman
sp
et
al
purpos
perform
test
primarili
establish
efficaci
drug
product
devic
deliveri
platform
address
test
elabor
chapter
usp
chapter
ug
aerosol
sirna
formul
dissolut
test
may
perform
ad
formul
within
dissolut
medium
vessel
constant
agit
shah
vp
et
al
son
yj
mcconvil
jt
solut
sampl
predetermin
time
interv
measur
amount
sirna
releas
nanoparticl
sinc
standard
method
develop
determin
sirna
dissolut
rate
variou
media
distil
water
dickinson
pa
et
al
phosphat
buffer
murata
n
et
al
simul
lung
fluid
slf
modifi
slf
use
addit
variou
apparatu
flowthrough
cell
davi
nm
feddah
mr
standard
usp
dissolut
apparatu
stir
vessel
use
test
condit
sink
particl
introduct
medium
either
direct
aerosol
use
character
dissolut
rate
inhal
drug
inerti
impact
standard
vitro
techniqu
use
predict
aerosol
deposit
lung
padhi
bk
et
al
cascad
impactor
equip
choic
particl
size
analysi
inhal
aerosol
allow
assay
mass
drug
determin
aerodynam
size
directli
provid
size
inform
indic
lung
deposit
inerti
sizesepar
fraction
cascad
sequenc
singl
stage
within
cascad
impactor
apparatu
measur
aerodynam
particl
size
distribut
apsd
chapter
ug
hickey
aj
jet
stream
aim
toward
flat
impact
plate
upon
flow
particl
high
inertia
disrupt
impact
plate
meanwhil
particl
lower
inertia
remain
within
streamlin
airflow
impact
onto
plate
chapter
ug
hickey
aj
merku
hg
sever
impactor
plate
separ
aerosol
particl
size
rang
accord
aerodynam
size
larger
particl
impact
plate
wherea
smaller
one
remain
airborn
stoke
number
defin
ratio
stop
distanc
orific
diamet
use
estim
impact
effici
mitchel
jp
nagel
mw
avail
cascad
impactor
accept
unit
state
pharmacopeia
usp
european
pharmacopeia
pheur
list
tabl
mitchel
jp
et
al
nichol
sc
et
al
andersen
cascad
impactor
aci
pharmacopei
method
pmdi
dpi
commonli
use
inerti
impactor
instrument
fig
cascad
impactor
includ
marplemil
model
fig
multistag
liquid
imping
fig
dpi
nebul
suggest
character
usp
pheur
use
nextgener
impactor
ngi
lmin
suitabl
valid
cascad
impactor
oper
lmin
nichol
sc
et
al
cascad
impactor
apparatus
measur
apsd
inhal
aerosol
lung
simul
model
mitchel
jp
nagel
mw
sinc
cascad
impactor
oper
constant
flow
rate
simul
environ
respiratori
tract
temperatur
rel
humid
sizeselect
variou
process
govern
deposit
human
respiratori
tract
constant
particl
veloc
within
cascad
impactor
contrast
decreas
air
veloc
increas
airway
gener
number
lung
cascad
impactor
stage
select
much
steeper
select
region
deposit
dunbar
c
mitchel
j
nonaerodynam
droplet
particl
size
distribut
determin
use
laser
diffract
chougul
et
al
de
boer
ah
et
al
padhi
bk
et
al
techniqu
measur
low
angl
scatter
monochromat
coher
light
everi
particl
measur
zone
simultan
measur
combin
contribut
angular
scatter
light
intens
profil
laser
diffract
advantag
noninvas
rapid
high
resolut
widedynam
rang
measur
volum
weight
particl
size
distribut
directli
absolut
techniqu
requir
calibr
verif
use
optic
reticl
lee
black
et
al
laser
diffract
particl
size
determin
measur
particl
size
scatter
light
posit
detector
array
smaller
particl
scatter
light
wider
angl
de
boer
ah
et
al
effici
data
invers
algorithm
ensur
rapid
converg
valid
solut
laser
diffract
method
util
interpret
relationship
scatter
light
intens
scatter
angl
distanc
central
axi
photodetector
fraunhof
approxim
simplifi
descript
assum
particl
absorb
light
complet
eshel
g
et
al
case
scatter
contour
consid
particl
refract
index
np
need
fraunhof
model
work
best
particl
size
much
larger
wavelength
light
particl
opaqu
spheric
np
differ
refract
index
surround
medium
eg
air
newman
sp
et
al
lorenzmi
theori
complet
descript
angular
light
scatter
process
requir
full
descript
complex
particl
refract
index
time
unknown
eshel
g
et
al
lorenzmi
model
appli
size
particl
assum
particl
homogen
isotrop
spheric
known
complex
np
incorpor
refract
absorpt
compon
timeaverag
data
present
mode
use
captur
overal
perform
pulmonari
inhal
product
size
distribut
present
differenti
cumul
format
key
metric
like
particl
size
th
th
th
volum
percentil
obtain
de
boer
ah
et
al
laser
diffract
equip
either
open
bench
close
cell
open
bench
simpl
perform
wide
use
aerosol
direct
across
measur
zone
close
sampl
necessari
dpi
test
may
need
control
evapor
measur
especi
continu
nebul
limit
laser
diffract
method
assay
drug
mass
particl
assum
spheric
constant
droplet
densiti
versu
size
vignet
beam
split
droplet
evapor
de
boer
ah
et
al
deliv
dose
uniform
assay
use
quantit
determin
deliv
dose
dose
uniform
use
dose
uniform
sampl
apparatu
dusa
chapter
ug
apparatu
connect
aerosol
deliveri
system
mouthpiec
adapt
vacuum
pump
connect
end
provid
desir
air
flow
aerosol
releas
sampl
apparatu
captur
onto
filter
assay
quantifi
deliv
dose
dose
uniform
determin
variabl
measur
deliv
dose
collect
total
mass
content
ex
vivo
studi
use
identifi
lungspecif
pk
without
interfer
system
absorpt
distribut
metabol
excret
adm
occur
vivo
studi
sakagami
isol
perfus
lung
method
includ
isol
lung
bodi
keep
within
artifici
system
certain
experiment
condit
test
util
isol
perfus
lung
model
maintain
lung
tissu
function
architectur
cryan
sa
et
al
sakagami
isol
perfus
lung
model
often
use
establish
mechan
drug
absorpt
deposit
lung
shortcom
ex
vivo
method
includ
rel
shorten
timefram
data
collect
due
viabil
perfus
lung
complex
experiment
set
absenc
tracheobronchi
circul
mucociliari
clearanc
cryan
sa
et
al
isol
perfus
lung
prepar
use
rat
guinea
pig
rabbit
dog
monkey
sakagami
prepar
shown
fig
b
consist
peristalt
pump
tube
assembl
carri
perfus
lung
doublejacket
artifici
thorax
hous
isol
perfus
lung
perfus
flow
normal
mlmin
rat
lung
pump
reservoir
isol
perfus
lung
central
porthol
thorax
lid
bottom
thorax
open
perfus
return
reservoir
collect
thorax
seal
enabl
neg
posit
pressur
ventil
mainten
pressur
sakagami
anim
anesthesia
pulmonari
circul
cannul
via
pulmonari
arteri
lung
perfus
autolog
whole
blood
buffer
artifici
medium
ph
sakagami
surgic
procedur
involv
prepar
isol
perfus
lung
model
discuss
previous
sakagami
follow
perfus
formul
administ
via
tracheal
port
perfus
sampl
may
collect
predetermin
time
point
establish
absorpt
profil
sakagami
gamma
scintigraphi
noninvas
imag
techniqu
allow
visual
drug
deposit
follow
pulmonari
deliveri
respiratori
tract
predict
vivo
efficaci
estim
mucociliari
clearanc
newman
wild
newman
sp
wild
ir
snell
n
ganderton
prior
pulmonari
deliveri
drug
formul
radiolabel
gammarayemit
radiotrac
technetium
altern
radiolabel
incorpor
attach
microparticl
nanocarri
instead
drug
nahar
k
et
al
radiolabel
could
simpli
achiev
mix
radiotrac
solut
formul
newman
sp
et
al
appropri
vitro
valid
requir
ensur
distribut
radiotrac
across
particl
size
rang
radiotrac
affect
particl
size
distribut
newman
wild
gamma
camera
use
visual
quantifi
drug
deposit
region
interest
within
respiratori
tract
follow
inhal
radiolabel
formul
scintigraphi
data
consid
equival
assess
tool
sinc
data
demonstr
correl
well
clinic
efficaci
data
bondesson
e
et
al
newman
wild
pulmonari
deliveri
formul
gamma
camera
scan
thorax
radioact
count
digit
get
imag
lung
oropharynx
stomach
inhal
devic
exhal
filter
major
c
et
al
nahar
k
et
al
peripheri
lung
imag
kr
ventil
transmiss
scan
superimpos
quantifi
gammalabel
particl
establish
distribut
permeat
conway
j
nahar
k
et
al
howev
two
dimension
natur
gamma
scintigraphi
imag
make
difficult
differenti
overlaid
anatom
structur
ratio
peripher
central
deposit
known
penetr
index
pi
measur
extent
aerosol
reach
lower
airway
lung
peripheri
conway
j
nahar
k
et
al
three
dimension
imag
method
singl
photon
emiss
comput
tomographi
spect
overcom
imag
issu
distinguish
physiolog
landmark
per
et
al
radiolabel
formul
track
gamma
camera
rotat
complet
around
subject
form
topograph
imag
plane
conway
j
fleme
j
et
al
nahar
k
et
al
imag
form
use
comput
softwar
snell
n
ganderton
limit
spect
possibl
occurr
region
deposit
redistribut
mucociliari
clearanc
cough
absorpt
bloodstream
min
method
timefram
huchon
gj
et
al
nahar
k
et
al
limit
requir
high
dose
use
radiat
vivo
imag
method
appli
overcom
issu
nevertheless
rel
lower
cost
technic
skill
requir
much
lower
planar
gamma
scintigraphi
spect
imag
everard
ml
nahar
k
et
al
spect
imag
suitabl
correl
vitro
vivo
data
chan
hk
et
al
eberl
et
al
snell
n
ganderton
positron
emiss
tomographi
pet
util
positron
label
drug
emit
two
highenergi
photon
electron
annihil
cherri
sr
gambhir
ss
dolovich
mb
nahar
k
et
al
phelp
photon
concurr
emit
one
anoth
detect
count
singl
event
nahar
k
et
al
accur
delin
region
interest
obtain
combin
pet
imag
mri
spiral
ct
scan
thorax
frauenfeld
et
al
yoon
sh
et
al
allow
calcul
percentag
inhal
dose
deposit
region
nahar
k
et
al
advantag
pet
drug
act
radioact
tracer
incorpor
positron
emit
isotop
c
n
f
cu
isotop
substitut
trace
amount
carvalho
tc
et
al
chakravarti
r
et
al
conway
j
park
cw
et
al
pet
employ
analyz
lung
patholog
biochemistri
inflamm
transgen
express
cellular
respons
vivo
park
cw
et
al
util
method
limit
short
halflif
c
min
radionuclid
necessit
need
close
cyclotron
studi
saha
gb
et
al
pet
suggest
advantag
planar
gamma
scintigraphi
pk
studi
calcul
total
lung
deposit
pulmonari
inhal
formul
nahar
k
et
al
snell
n
ganderton
magnet
reson
imag
mri
requir
radiolabel
aerosol
determin
qualit
quantit
deposit
particl
lung
rather
base
nuclear
magnet
reson
phenomenon
method
util
nonioniz
radiat
gener
imag
augment
use
soft
tissu
contrast
mechan
orient
imag
nahar
k
et
al
interact
nuclear
magnet
moment
experiment
sampl
tissu
extern
magnet
electromagnet
field
form
spin
densiti
relax
time
motion
rang
diffus
rapid
produc
signal
mri
equip
util
form
imag
depend
local
nuclei
environ
subject
diseas
state
tissu
longitudin
relax
time
constant
transvers
relax
time
constant
nahar
k
et
al
thompson
rb
finlay
wh
signal
measur
nuclei
either
full
half
integ
valu
spin
proport
angular
momentum
result
odd
number
proton
neutron
major
mri
measur
signal
ubiquit
hydrogen
h
atom
howev
lung
imag
perform
use
heliumbas
method
well
establish
nonlipid
solubl
properti
helium
allow
stay
within
airspac
komlosi
p
et
al
kruger
sj
et
al
nahar
k
et
al
hyperpolar
xe
ga
mri
produc
polar
lead
better
imag
mosbah
k
et
al
taratula
dmochowski
ij
thompson
rb
finlay
wh
mri
employ
within
vivo
anim
studi
within
vitro
human
lung
airway
replica
martin
ar
et
al
sood
bg
et
al
sood
bg
et
al
thompson
rb
finlay
wh
wang
h
et
al
fluoresc
imag
track
fluoresc
tag
particl
within
aerosol
monitor
deposit
lung
nahar
k
et
al
ntziachristo
v
et
al
method
limit
due
issu
excit
emiss
fluoresc
signal
scatter
reflect
absorb
tissu
nahar
k
et
al
yi
et
al
affect
light
captur
detector
actual
number
molecul
addit
heterogen
background
signal
exist
biolog
tissu
capabl
autofluoresc
yi
et
al
autofluoresc
background
measur
use
untreat
tissu
subtract
experiment
background
use
nearinfrar
wavelength
use
overcom
issu
adam
ke
et
al
comsa
dc
et
al
kovar
jl
et
al
murata
et
al
fluoresc
dye
aerosol
deliv
lung
via
inhal
intrach
intranas
rout
imag
use
vivo
imag
system
ivi
particl
deposit
lobe
lung
visual
quantifi
use
imag
analyz
softwar
nahar
k
et
al
fluoresc
imag
elimin
need
radioact
tag
therefor
may
use
imag
deposit
pattern
live
anim
ntziachristo
v
et
al
pk
studi
investig
adm
drug
collect
lung
deposit
plasma
concentr
data
either
anim
human
test
subject
determin
pk
paramet
paramet
includ
drug
absorpt
paramet
peak
drug
concentr
c
max
time
c
max
occur
max
absorpt
rate
constant
k
determin
absorpt
rate
area
curv
auc
estim
bioavail
also
drug
distribut
elimin
paramet
clearanc
cl
volum
distribut
vd
halflif
drug
determin
mice
rat
anim
model
commonli
use
anim
pk
studi
develop
model
variou
respiratori
diseas
smaller
drug
requir
low
cost
cryan
sa
et
al
sakagami
drug
administ
intranas
intratrach
rout
use
passiv
inhal
cryan
sa
et
al
sakagami
zhang
j
et
al
intratrach
intranas
direct
administr
avoid
oropharyng
deposit
enabl
accur
reproduc
dose
chiang
pc
et
al
clinic
use
sirna
need
deliv
target
region
lung
releas
within
cytoplasm
enter
target
cell
shown
fig
success
gene
therapi
requir
effect
level
transgen
express
specif
cell
type
enhanc
treatment
efficaci
avoid
advers
side
effect
caus
express
inappropri
cell
type
sirna
highli
neg
charg
hydrophil
larg
size
approxim
kda
macromolecul
cross
biolog
membran
reach
target
site
viral
vector
previous
demonstr
cell
uptak
sirna
efficaci
howev
major
limit
human
therapeut
deliveri
exist
uncontrol
viral
replic
immunogen
tumorigen
toxic
thoma
ce
et
al
due
concern
nonvir
deliveri
system
develop
success
use
deliv
sirna
ideal
sirna
deliveri
system
condens
sirna
nanos
particl
protect
sirna
enzymat
degrad
facilit
cellular
uptak
promot
endosom
escap
releas
sirna
cytoplasm
risc
locat
neglig
effect
gene
silenc
activ
specif
neglig
toxic
lam
jkw
et
al
merkel
om
et
al
nonvir
deliveri
system
includ
nake
sirna
deliveri
deliveri
vector
lipid
polym
peptid
inorgan
materi
deliv
sirna
effici
lung
via
pulmonari
rout
requir
understand
anatom
physiolog
characterist
respiratori
tract
human
respiratori
tract
highli
effici
ga
exchang
capac
keep
particul
tabl
discuss
previous
merkel
om
et
al
therefor
develop
sirna
aerosol
deliveri
system
consid
care
control
particl
droplet
size
bypass
lung
natur
defens
mechan
respiratori
tract
divid
two
region
conduct
airway
respiratori
region
conduct
airway
encompass
nasal
caviti
pharynx
trachea
bronchi
bronchiol
respiratori
region
consist
respiratori
bronchiol
alveoli
lam
jkw
et
al
human
respiratori
tract
evolv
size
select
fraction
prevent
particul
reach
deep
lung
exampl
largest
particl
remov
nasoor
oropharynx
progress
finer
particl
deposit
proxim
intermedi
distal
airway
main
featur
respiratori
tract
high
degre
bifurc
describ
accord
weibel
lung
model
gener
total
gradual
narrow
airway
carina
alveolar
sac
caus
increas
particl
veloc
caus
particl
impact
wall
airway
instead
reach
lower
region
lung
therefor
therapeut
agent
reach
target
site
action
must
possess
aerodynam
properti
allow
pass
branch
airway
deep
lung
aerodynam
particl
size
distribut
import
influenc
locat
lung
deposit
formul
bisgaard
h
et
al
three
forc
domin
particl
motion
within
aerosol
cloud
gravit
sediment
inerti
impact
brownian
diffus
gravit
sediment
inerti
impact
domin
aerodynam
diamet
larg
particl
aerodynam
particl
size
deposit
mostli
airway
wall
bifurc
upper
airway
due
high
momentum
smaller
particl
aerodynam
diamet
deposit
due
brownian
diffus
f
submicron
size
particl
deliv
without
larger
carrier
particl
droplet
would
mostli
exhal
breath
breath
hold
method
may
use
increas
deposit
within
lower
respiratori
tract
howev
lower
effici
optimum
aerodynam
particl
size
deposit
within
lower
airway
agu
ru
et
al
sakagami
particl
size
decreas
lung
deposit
increas
due
increas
diffusion
mobil
yang
w
et
al
particl
less
nm
size
approxim
nanoparticl
deposit
within
alveolar
region
lung
nanoparticl
often
enter
lung
larg
agglomer
break
apart
upon
deposit
elimin
pathway
nanoparticl
within
lung
involv
cough
dissolut
clearanc
via
mucociliari
escal
transloc
airway
phagocytosi
macrophag
neuron
uptak
roy
vij
n
sander
n
et
al
zhang
j
et
al
nanoparticl
degrad
depend
composit
deliveri
system
mediat
hydrolysi
oxid
reduct
pathway
roy
vij
n
ryt
e
et
al
deposit
lower
airway
follow
inhal
free
sirna
suscept
degrad
rnase
whose
enzymat
activ
high
lung
amatngalim
gd
et
al
morita
et
al
sorrentino
major
pulmonari
deliveri
barrier
mucociliari
clearanc
driven
physic
action
ciliat
epitheli
cell
move
mucu
alveolar
fluid
toward
upper
airway
eventu
throat
mucociliari
clearanc
also
includ
alveolar
macrophag
along
airway
phagocytos
foreign
particl
deposit
remain
remov
mucociliari
escal
mucu
present
respiratori
epithelium
nasal
caviti
termin
bronchiol
knowl
mr
boucher
rc
type
glycosyl
protein
known
mucin
main
compon
mucu
rose
mc
et
al
mucu
physic
barrier
increas
viscos
moist
surfac
lung
epitheli
cell
therebi
reduc
drug
penetr
diffus
rate
mellnik
j
et
al
particl
deposit
mucos
layer
ciliat
epitheli
cell
rapidli
remov
mucociliari
clearanc
eventu
either
cough
swallow
gastrointestin
tract
knowl
mr
boucher
rc
rubin
bk
alveolar
fluid
found
surfac
alveoli
epithelium
thin
layer
pulmonari
surfact
compos
phospholipid
surfactantassoci
protein
known
spa
spb
spc
spd
bastacki
j
et
al
possmay
f
et
al
follow
deliveri
foreign
antigen
nanocarri
pulmonari
surfact
protein
spa
spd
shown
play
role
macrophag
uptak
act
opsonin
scaveng
molecul
kishor
u
et
al
pulmonari
surfact
locat
airliquid
interfac
alveoli
therefor
interact
particul
aerosol
reach
lower
airway
seaton
ba
et
al
major
opsonin
airway
alveoli
lung
includ
immunoglobulin
igg
igm
complement
fragment
fibronectin
laminin
kuroki
et
al
patel
b
et
al
alveolar
macrophag
locat
within
alveoli
rapidli
engulf
foreign
particl
phagocytosi
defens
mechan
patton
j
weinberg
b
et
al
zhao
f
et
al
addit
macrophag
major
phagocyt
neutrophil
polymorphonuclear
neutrophil
leukocyt
pmn
poli
abund
blood
present
normal
healthi
tissu
kolaczkowska
e
kube
p
like
macrophag
neutrophil
phagocyt
cell
role
innat
immun
recogn
ingest
destroy
mani
pathogen
without
adapt
immun
respons
kolaczkowska
e
kube
p
macrophag
first
encount
pathogen
within
lung
action
augment
recruit
larg
number
neutrophil
infect
site
burn
ar
et
al
kolaczkowska
e
kube
p
pulmonari
administ
nake
sirna
suscept
alveolar
macrophag
neutrophil
uptak
subsequ
degrad
within
cell
thu
reduc
therapeut
efficaci
consid
diseas
state
import
aspect
pulmonari
clearanc
sinc
physiolog
condit
airway
alter
pose
threat
effici
aerosol
sirna
deliveri
system
infect
inflamm
airway
becom
congest
increas
mucu
secret
decreas
mucociliari
clearanc
groneberg
et
al
patton
js
et
al
thick
viscos
viscoelast
composit
mucu
layer
depend
patholog
condit
interpati
variabl
sander
n
et
al
differ
therapeut
applic
diseas
state
patient
consid
order
design
effect
aerosol
deliveri
system
addit
use
particl
small
aerodynam
diamet
suitabl
deposit
lower
airway
report
use
larg
porou
particl
prolong
retent
time
lung
effect
avoid
alveolar
macrophag
phagocytosi
arnold
mm
et
al
benjebria
et
al
edward
da
et
al
porou
particl
geometr
diamet
smaller
aerodynam
diamet
due
massinertia
relationship
smaller
aerodynam
diamet
fall
within
ideal
aerodynam
size
rang
effect
lung
deposit
actual
geometr
size
larger
size
rang
alveolar
macrophag
uptak
remov
mucu
layer
may
partial
deterior
use
mucolyt
agent
break
three
dimension
gel
network
mucu
mucu
inhibitor
glucopyrrol
may
also
use
overcom
mucu
barrier
ferrari
et
al
patient
bronchiectasi
cystic
fibrosi
mannitol
clinic
proven
improv
hydrat
viscoelast
surfac
properti
sputum
increas
mucu
clearanc
daviska
e
et
al
deposit
site
nucleic
acid
deliveri
system
airway
previous
manipul
direct
use
ultrasound
magnet
field
technolog
dame
p
et
al
xenari
et
al
xenari
et
al
anoth
lessinvas
option
enhanc
transport
across
mucu
layer
coat
surfac
nanoparticl
neutral
charg
molecul
like
polyethylen
glycol
peg
schuster
bs
et
al
lung
diseas
involv
chronic
lung
inflamm
like
cystic
fibrosi
emphysema
asthma
character
increas
level
pulmonari
proteas
green
cm
mcelvaney
ng
proteas
may
degrad
peptid
conjug
sirna
polymer
nanocarri
sirna
carrier
get
target
specif
cell
interest
exert
effect
sirna
must
cross
cellular
membran
releas
within
cytoplasm
target
cell
respiratori
tract
must
access
risc
intracellular
interact
take
place
due
size
kda
neg
charg
sirna
readili
cross
biolog
membran
therefor
appropri
deliveri
system
facilit
sirna
cellular
uptak
major
cellular
uptak
pathway
nonvir
sirna
deliveri
system
nm
size
endocytosi
khalil
ia
et
al
endocytosi
mechan
cell
engulf
polar
molecul
nanocarri
readili
pass
hydrophob
cellular
membran
four
endocytosi
pathway
clathrinmedi
endocytosi
caveolaemedi
endocytosi
micropinocytosi
phagocytosi
marsh
inhal
rout
administr
particl
size
less
nm
also
avoid
macrophag
uptak
thu
slow
lung
clearanc
lebhardt
et
al
clathrinmedi
endocytosi
major
pathway
allow
particl
uptak
enclos
clathrinco
vesicl
khalil
ia
et
al
vesicl
fuse
earli
endosom
form
late
endosom
subsequ
form
lysosom
process
progress
earli
endosom
lysosom
ph
within
vesicl
drop
approxim
ph
degrad
dnase
rnase
present
within
lysosom
balli
mb
et
al
khalil
ia
et
al
maxfield
fr
mcgraw
te
sirna
elicit
therapeut
effect
within
cell
must
escap
endosom
releas
within
cytoplasm
avoid
degrad
degrad
enzym
promot
endosom
escap
proton
spong
hypothesi
practic
use
high
buffer
capac
polym
larg
ph
rang
polyethylenimin
pei
becom
proton
ph
endosom
drop
boussif
et
al
gunther
et
al
proton
polym
caus
influx
chlorid
ion
proton
water
endosom
build
osmot
pressur
caus
endosom
burst
thu
releas
content
cytoplasm
gunther
et
al
howev
use
pei
associ
toxic
issu
seow
wy
et
al
altern
strategi
promot
endosom
escap
use
ph
sensit
fusogen
peptid
peptid
undergo
phdepend
conform
chang
low
ph
caus
membran
disrupt
conform
chang
destabil
endosom
membran
choi
sw
et
al
kusumoto
k
et
al
lee
sh
et
al
oliveira
et
al
anoth
cellular
uptak
mechan
sirna
deliveri
system
caveolaemedi
endocytosi
pathway
khalil
ia
et
al
deliveri
system
intern
caveolinco
vesicl
known
caveosom
caveosom
void
nucleas
degrad
enzym
nonacid
ph
deliveri
system
avoid
lysosom
degrad
content
caveosom
transport
golgi
endoplasm
reticulum
caveolin
express
within
lung
tissu
therefor
may
effici
rout
inhal
sirna
deliveri
system
compar
clathrinmedi
endocytosi
especi
deliveri
system
nt
possess
endosom
escap
properti
lam
jkw
et
al
parton
rg
richard
aa
yacobi
nr
et
al
anoth
cellular
uptak
mechan
cell
lung
phagocytosi
khalil
ia
et
al
rout
perform
alveolar
macrophag
special
cell
unless
target
cell
type
alveolar
macrophag
uptak
deliveri
system
pathway
avoid
sinc
sirna
molecul
taken
eventu
degrad
phagolysosom
cell
lower
airway
pulmonari
deliveri
achiev
inhal
aerosol
deliveri
devic
pmdi
dpi
nebul
smi
preclin
safeti
efficaci
studi
use
anim
model
often
deliv
pulmonari
aerosol
via
inhal
intratrach
intranas
rout
lung
physiolog
anatom
differ
human
anim
integr
consider
select
rout
administr
assess
efficaci
aerosol
intratrach
administr
involv
invas
surgic
setup
anesthesia
intranas
rout
administr
use
reach
airway
mous
model
instil
aspir
liquid
solut
suspens
nasal
caviti
anim
dri
powder
formul
deliv
use
microspray
actuat
gener
aerosol
propel
airway
noseonli
exposur
chamber
use
preclin
studi
provid
robust
mean
deliv
aerosol
deep
lung
aerosol
sirna
formul
character
use
vitro
ex
vivo
vivo
techniqu
vitro
techniqu
measur
dissolut
rate
aerodynam
particl
size
distribut
total
deliveri
dose
uniform
particl
size
aerosol
veloc
ex
vivo
techniqu
analyz
mechan
drug
transport
deposit
absorpt
vivo
techniqu
provid
visual
quantif
aerosol
deposit
respiratori
tract
pk
paramet
biochem
physiolog
effect
pulmonari
deliv
drug
barrier
pulmonari
deliveri
sirna
exist
due
natur
defens
lung
keep
exogen
particul
substanc
deliv
aerosol
sirna
effect
lung
target
siteofact
involv
understand
anatom
physiolog
characterist
respiratori
tract
barrier
aerosol
deliveri
sirna
includ
degrad
rnase
mucociliari
clearanc
intracellular
nake
sirna
deliveri
imped
due
larg
size
neg
charg
suscept
degrad
intracellular
deliveri
constraint
may
mitig
use
sirna
nanocarri
system
aerosol
deliveri
includ
lipid
polymer
peptid
inorgan
origin
part
ii
review
articl
discuss
prepar
method
variou
sirna
nanocarri
system
accompani
seri
exampl
